22 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Immunotherapy
  • Germany
  • World
  • Product Initiative
  • Anergis SA

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy Immunotherapy
  • Immunotherapy
  • World
  • Product Initiative
  • Anergis SA

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • United States
  • Aimmune Therapeutics, Inc.

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Biotechnology
  • Immunotherapy
  • United States
  • Product Initiative

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • Therapy
  • Biomay AG

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • Therapy
  • Biomay AG

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Immunotherapy
  • Medical Biotechnology
  • United States
  • World
  • Product Initiative

" House dust mite allergy is one of the most common allergies, impacting the quality of life for patients across ages and geographies.

  • Immunotherapy
  • Medical Biotechnology
  • United States
  • World
  • Product Initiative

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Biotechnology
  • Immunotherapy
  • Therapy
  • Product Initiative

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy Drug
  • Immunotherapy
  • Ophthalmic Solution
  • Pharmaceutical
  • Product Initiative

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Antifungal
  • Blood Disease
  • Immunotherapy
  • Therapy
  • Bristol-Myers Squibb Company

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Chronic Disease
  • Immunotherapy
  • Respiratory Disease
  • United States
  • Product Initiative

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Blood Disease
  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • United States

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Immunotherapy
  • Therapy
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Immunotherapy
  • Monoclonal Antibody
  • United States
  • Product Initiative

About ## percent of people who have food allergies are allergic to more than one food.

  • Immunotherapy
  • Monoclonal Antibody
  • Respiratory Disease
  • United States
  • Product Initiative

Rituximab was well tolerated, and most adverse drug reactions were grade ##-## in severity.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Immunotherapy
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

PI##-Kinase delta is expressed primarily in blood cell lineages, including cells that cause or mediate hematologic malignancies, inflammation, autoimmune diseases and allergies.

  • Immunotherapy
  • Lymphoma
  • Therapy
  • United States
  • Product Initiative

This explains the need for a high drug dose of IXF-## as supported by the findings of the recently published post-hoc analysis.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Immunotherapy
  • Infectious Disease
  • United States
  • SCYNEXIS, Inc.